Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Portfolio Pulse from Avi Kapoor
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is set to release its Q4 earnings on Feb. 5, 2024, with analysts predicting an EPS of $4.10, up from $3.76 year-over-year, and revenue of $2.51 billion, up from $2.3 billion. The company recently announced positive results from its Phase 3 trials for VX-548. Shares fell 2.1% to $424.68 recently. Analysts from JP Morgan, Truist Securities, Canaccord Genuity, RBC Capital, and HC Wainwright & Co. have updated their ratings and price targets for VRTX.
February 05, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals is anticipated to report increased Q4 earnings and revenue. Positive Phase 3 trial results for VX-548 could influence stock performance, despite a recent 2.1% drop in share price.
The anticipation of higher earnings and revenue for Q4, combined with positive trial results for VX-548, suggests a potential positive short-term impact on VRTX's stock price. The recent drop in share price might be seen as a temporary setback if the earnings report meets or exceeds expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100